Sign inJoin waitlistJoin the waitlist

Ali Habib

Program Director — Neuromuscular Medicine Fellowship, Neurology · University of California

Credentials: · · · · ·

History

Neuromuscular Medicine, Neurology Fellowship · University of California
Present
Advanced Neuromuscular Medicine, Neurology Fellowship · University of California
Present
University of California
Present

Clinical Neurophysiology
2010–2011
Neuromuscular Medicine
New York Presbyterian Hospital
2009–2010
Neurology
New York Presbyterian Hospital
2004–2008
Aga Khan Med Coll, Karachi, Pakistan
1997–2001

Research

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
The Lancet Neurology · 2023 · 231 citations
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2…
JAMA Neurology · 2020 · 154 citations
Emerging drugs for amyotrophic lateral sclerosis
Review · Expert Opinion on Emerging Drugs · 2011 · First of 2 authors · Corresponding · 35 citations

Tuan Vu
9 papers
TM
Tahseen Mozaffar
8 papers
Henry Kaminski
7 papers
James Howard
7 papers
Michael Pulley
6 papers
Gil Wolfe
5 papers
David Walk
4 papers
Hiroshi Mitsumoto
4 papers
Ikjae Lee
4 papers
Kelly Gwathmey
4 papers
Richard Nowak
4 papers
Catherine Lomen-Hoerth
3 papers

Clinical trials

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2033
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Site PI · Recruiting · Phase 1, Phase 2
Cabaletta Bio
2024–2029
Vitaccess Real MG Registry
Site PI · Recruiting
Vitaccess Ltd
2024–2034